Home > Boards > US Listed > Medical - Equipment > Itamar Medical Ltd. (ITMR)

Itamar Medical Receives CE Mark Approval for its

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 128
Posts 26,151
Boards Moderated 4
Alias Born 02/07/04
160x600 placeholder
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 12/16/2021 4:11:41 PM
Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse) Edgar (US Regulatory) - 12/16/2021 8:42:15 AM
Itamar Medical EPS beats by $0.23, beats on revenue Seeking Alpha - 11/18/2021 6:24:10 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/18/2021 6:04:28 AM
Itamar Medical Reports Third Quarter 2021 Financial Results GlobeNewswire Inc. - 11/18/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/16/2021 4:06:47 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/14/2021 5:21:24 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/4/2021 6:05:02 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 9/13/2021 5:28:31 PM
ATER, AXTI and OIIM among mid-day movers Seeking Alpha - 9/13/2021 1:25:44 PM
Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a) Edgar (US Regulatory) - 8/12/2021 8:25:03 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/12/2021 6:36:47 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/12/2021 6:31:21 AM
Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors GlobeNewswire Inc. - 8/12/2021 6:00:00 AM
Itamar Medical Reports Second Quarter 2021 Financial Results GlobeNewswire Inc. - 8/10/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 7/28/2021 6:08:19 AM
Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 10, 2021 GlobeNewswire Inc. - 7/28/2021 6:00:00 AM
Teleflex and Itamar sell off “too draconian”: Piper Sandler Seeking Alpha - 7/16/2021 4:57:40 PM
Itamar Medical to Present at the Ladenburg Thalmann Annual Healthcare Conference on Wednesday, July 14, 2021 GlobeNewswire Inc. - 6/30/2021 6:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 6/17/2021 11:07:41 AM
Itamar Medical Launches Enhancements to WatchPAT™ Product Line at SLEEP 2021 GlobeNewswire Inc. - 6/7/2021 6:00:00 AM
Itamar Medical Appoints Brad Fluegel to its Board of Directors GlobeNewswire Inc. - 5/24/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/20/2021 6:09:20 AM
Itamar Medical EPADS beats by $0.01, beats on revenue Seeking Alpha - 5/19/2021 6:03:06 AM
Itamar Medical Reports First Quarter 2021 Results GlobeNewswire Inc. - 5/19/2021 6:00:00 AM
midastouch017   Monday, 05/04/20 06:17:56 AM
Re: None
Post # of 12 
Itamar Medical Receives CE Mark Approval for its WatchPAT™ ONE, the First Fully Disposable Home Sleep Apnea Test

GlobeNewswire GlobeNewswire•May 4, 2020

Complete, home-based solution for diagnosing respiratory sleep disorders approved for commercialization in Europe and other CE Mark geographies

CAESAREA, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical solutions to aid in the diagnosis of respiratory sleep disorders, today announced receipt of CE mark approval for the Company’s WatchPAT™ ONE. The CE mark allows Itamar to expand commercialization of the latest innovation of its WatchPAT technology and the first fully disposable Home Sleep Apnea Test (HSAT), throughout Europe and other CE Mark geographies.

“We are pleased to now have the opportunity to expand availability of our WatchPAT ONE in Europe, following rapidly growing adoption in the US,” said Gilad Glick, President and Chief Executive Officer of Itamar Medical. “We are excited to be able to provide our cutting-edge technology to benefit physicians, as well as patients that are subject to social distancing, in light of the current COVID-19 related healthcare crisis. Importantly, our solution eliminates the need for return shipping, downloading, cleaning, and preparation, thus significantly reducing patient and staff exposure. Additionally, we remain enthusiastic about WatchPAT ONE’s potential in the inpatient setting, where infection transmission through reusable devices is top of mind.”

About WatchPAT ONE
WatchPAT ONE was designed to deliver both ease of use and accessibility. With WatchPAT ONE, patients simply pair the WatchPAT device to their smartphone using Itamar’s proprietary App during their Home Sleep Apnea Test. Once the test is complete and the data is automatically transmitted to Itamar’s secure CloudPAT™ server, the prescribing physician receives an automatically generated, comprehensive report based on WatchPAT’s True Sleep Time, Sleep Architecture and Central Plus algorithms. The patient is then able to dispose the WatchPAT device without any further action required. WatchPAT ONE received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in July 2019 and is currently available in the U.S., Europe and Australia.

https://finance.yahoo.com/news/itamar-medical-receives-ce-mark-100010491.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences